ClinicalTrials.gg
RecruitingNCT05719441Updated Oct 14, 2026

A Clinical Trial of Combination HIV-Specific Broadly Neutralizing Monoclonal Antibodies Combined With ART Initiation During Acute HIV Infection to Induce HIV Remission

A Phase 2 interventional study of VRC07-523LS and PGT121.414.LS in Acute HIV Infection, sponsored by National Institute of Allergy and Infectious Diseases (NIAID). Recruiting at 12 sites in 3 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by National Institute of Allergy and Infectious Diseases (NIAID) · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2024; still recruiting 2 years 3 months later.
Updated Oct 14, 2026Site recruiting status changedPrimary completion moved+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,034 studies in HIV Infections by National Institute of Allergy and Infectious Diseases (NIAID) — 10 open to participants now, 15 under way, 1 of them phase 3. HIV Infections · National Institute of Allergy and Infectious Diseases (NIAID).

Planned enrollment
497th of 883
48 · median 59
Started
2024
with 5 others
Phase 2
225 of 1,034
2 open now
Primary completion
2028-07
later than 10 of 12 live
Registered
1,024th of 1,034
by date

Among the 1,034 studies in HIV Infections by National Institute of Allergy and Infectious Diseases (NIAID), this one is the 497th largest by planned enrollment of the 883 interventional ones that give a count, is one of 6 that started in 2024, is one of 225 in phase 2, reaches primary completion later than 10 of the 12 other live ones, and was the 1,024th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

10 of the 1,034 studies in HIV Infections by National Institute of Allergy and Infectious Diseases (NIAID) are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,034 studies in HIV Infections by National Institute of Allergy and Infectious Diseases (NIAID), or all of them as a file.
02

Study summary

A5388 is a phase II, two-arm, randomized, double-blind, placebo-controlled study that will enroll 48 antiretroviral therapy (ART)-naïve adults with acute HIV infection (AHI) in order to determine whether:

  • Administration of combination HIV-specific broadly neutralizing antibody (bNAb) therapy in addition to ART during acute HIV infection (AHI) will be safe.
  • Participants who receive combination bNAb therapy in addition to ART during AHI will be more likely to demonstrate a delay in time to HIV-1 RNA ≥1,000 copies/mL for 4 consecutive weeks during an Analytical Treatment Interruption (ATI) compared to participants who receive placebo plus ART.
  • Participants who receive combination bNAb therapy in addition to ART during AHI will demonstrate lower viral reservoirs and enhanced HIV-specific immunity compared to participants who receive placebo plus ART.
03

Conditions studied

  • Acute HIV Infection

Browse trials for

Keywords

  • Acute HIV Infection
  • Broadly Neutralizing Antibodies
  • Analytical Treatment Interruption
  • Viral Reservoir
04

Who can participate

The criteria were revised on the registry on Oct 14, 2026. See what changed

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

  • Between 18 and 70 years of age
  • Body weight under 115 kg (approximately 253 pounds)
  • Evidence of recently acquiring
  • Not pregnant or breastfeeding
  • No recent use of medications to prevent or treat HIV
  • Able and willing to provide to study and its procedures which include

    • initiating HIV medications (also called antiretroviral treatment or ART) following enrollment,
    • A later, monitored pause in HIV medications (also called an analytical treatment interruption, or ATI)
  • While pausing HIV treatment per study guidelines until resuppressed following treatment restart, agree to using barrier to prevent HIV acquisition in sexual partners
  • Agree to use effective contraception to prevent pregnancy in oneself and sexual partners who may become pregnant.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    Arm 1: VRC07-523LS + PGT121.414.LS + ART

    Biological: VRC07-523LS · Biological: PGT121.414.LS · Drug: ART

  • Placebo comparator
    Arm 2: Placebo + ART

    Other: Placebo · Drug: ART

Interventions

  • BiologicalVRC07-523LS

    10 mg/kg intravenous infusion over approximately 15 to 30 minutes once at entry

    Also known as: VRC-HIVMAB075-00-AB

  • BiologicalPGT121.414.LS

    5 mg/kg intravenous infusion over approximately 30 to 60 minutes once at entry

    Also known as: VRC-HIVMAB0107-00-AB

  • OtherPlacebo

    Sodium Chloride for Injection USP, 0.9%

  • DrugART

    Bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablet orally once daily with or without food

    Also known as: Biktarvy

06

What researchers measure

Primary outcomes

  1. Occurrence of Grade ≥2 AE or SAE that are possibly, probably, or definitely related to the study bNAbs during initial ART treatment

    Time frame: Week 0 to end of initial ART treatment (scheduled to be 60 weeks)

  2. Time from ART discontinuation to HIV-1 RNA ≥1,000 copies/mL for 4 consecutive weekly measurements during analytical treatment interruption (ATI)

    Time frame: From start of ATI through 24 weeks after ART interruption

Secondary outcomes

  1. Time from ART discontinuation to first documented HIV-1 RNA viral rebound of ≥50 copies/mL during ATI

    Time frame: From start of ATI through 24 weeks after ART interruption

  2. Time from ART discontinuation to first documented HIV-1 RNA viral rebound of ≥200 copies/mL during ATI

    Time frame: From start of ATI through 24 weeks after ART interruption

  3. Time from ART discontinuation to first documented HIV-1 RNA viral rebound of ≥1000 copies/mL during ATI

    Time frame: From start of ATI through 24 weeks after ART interruption

  4. Proportion of study participants who undergo ATI with HIV-1 RNA <200 copies/mL at 24 weeks after ART interruption, without indication of ART restart

    Time frame: From start of ATI through 24 weeks after ART interruption

  5. Time from ART discontinuation to ART restart for an HIV-related reason (virologic, immunologic and clinical criteria) during ATI

    Time frame: From start of ATI through 24 weeks after ART interruption

  6. Frequency of participants maintained off ART at each visit during ATI

    Time frame: From start of ATI through 24 weeks after ART interruption

  7. Change in CD4+/CD8+ T-cell counts during ATI

    Time frame: From start of ATI through 24 weeks after ART interruption

  8. Area under the curve (AUC) of VRC07-523LS and PGT121.414.LS when administered together

    Time frame: Week 0 to end of ATI

  9. Half-life of VRC07-523LS and PGT121.414.LS when administered together

    Time frame: Week 0 to end of ATI

  10. Cmax of VRC07-523LS and PGT121.414.LS when administered together

    Time frame: Week 0 to end of ATI

  11. Cmin of VRC07-523LS and PGT121.414.LS when administered together

    Time frame: Week 0 to end of ATI

  12. Clearance (Cl/F) of VRC07-523LS and PGT121.414.LS when administered together

    Time frame: Week 0 to end of ATI

  13. Volume of distribution of VRC07-523LS and PGT121.414.LS when administered together

    Time frame: Week 0 to end of ATI

07

Study locations

11 of 12 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Individual participant data that underlie results in the publication, after deidentification.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Beginning 3 months following publication and available throughout period of funding of the AIDS Clinical Trials Group by NIH.

Access criteria: With whom? Researchers who provide a methodologically sound proposal for use of the data that is approved by the AIDS Clinical Trials Group. For what types of analyses? To achieve aims in the proposal approved by the AIDS Clinical Trials Group. By what mechanism will data be made available? Researchers may submit a request for access to data using the AIDS Clinical Trials Group "Data Request" form at: https://actgnetwork.org/aboutactg/templates-and-forms. Researchers of approved proposals will need to sign an AIDS Clinical Trials Group Data Use Agreement before receiving the data.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for Jul 2028, 46 months after the start.

Of 64 non-industry phase 2 interventional studies under HIV Infections, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 74. This study's planned 46 months is above that.

Counting every sponsor, half of 98 studies reached it within 31 months; a quarter within 17 and three quarters within 58.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 14, 2026: primary completion Apr 2028 → Jul 2028 and completion Sep 2028 → Jun 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 30, 2023
First posted
Feb 9, 2023
StartActual
Aug 19, 2024
Primary completionEst.
Jul 17, 2028was Apr 2028
CompletionEst.
Jun 18, 2029was Sep 2028
Last update
Oct 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added, 26 sites removed. 3 sites changed recruiting status (3 now recruiting)
Show 3 sites
  • 2701, Northwestern University CRS · Chicago, United StatesNot yet recruiting→Recruiting
  • 6201, Penn Therapeutics CRS · Philadelphia, United StatesNot yet recruiting→Recruiting
  • 11301, Barranco CRS · Lima, PeruNot yet recruiting→Recruiting
Show 2 added (1 United States, 1 Brazil)
  • 31473, Houston Advancing Research Team CRS · Houston, United States
  • 12201, Instituto de Pesquisas em AIDS do Rio Grande do Sul - IPARGS CRS · Porto Alegre, Brazil
Show 26 removed
  • 1201, University of Southern California CRS · Los Angeles, United States
  • 601, University of California, Los Angeles CARE Center CRS · Los Angeles, United States
  • 701, UCSD Antiviral Research Center CRS · San Diego, United States
  • 801, University of California, San Francisco HIV/AIDS CRS · San Francisco, United States
  • 603, Harbor University of California Los Angeles Center CRS · Torrance, United States
  • 31791, Whitman-Walker Institute, Inc. CRS · Washington D.C., United States
  • 2702, Rush University CRS · Chicago, United States
  • 201, Johns Hopkins University CRS · Baltimore, United States
  • 101, Massachusetts General Hospital CRS (MGH CRS) · Boston, United States
  • 107, Brigham and Women's Hospital Therapeutics (BWH TCRS) CRS · Boston, United States
  • 2101, Washington University Therapeutics (WT) CRS · St Louis, United States
  • 7804, Weill Cornell Chelsea CRS · New York, United States
  • 30329, Columbia Physicians & Surgeons (P&S) CRS · New York, United States
  • 7803, Weill Cornell Uptown CRS · New York, United States
  • 31787, University of Rochester Adult HIV Therapeutic Strategies Network CRS · Rochester, United States
  • 3201, Chapel Hill CRS · Chapel Hill, United States
  • 3203, Greensboro CRS · Greensboro, United States
  • 2401, Cincinnati CRS · Cincinnati, United States
  • 2501, Case CRS · Cleveland, United States
  • 1001, University of Pittsburgh CRS · Pittsburgh, United States
  • 2951, The Miriam Hospital (TMH) CRS · Providence, United States
  • 3652, Vanderbilt Therapeutics (VT) CRS · Nashville, United States
  • 31443, Trinity Health and Wellness Center CRS · Dallas, United States
  • 31473, Houston AIDS Research Team CRS · Houston, United States
  • 12201, Hospital Nossa Senhora da Conceicao CRS · Porto Alegre, Brazil
  • 11302, San Miguel CRS · San Miguel, Peru
Oct 14, 2026
Primary completion
Apr 6, 2028→Jul 17, 2028
Oct 14, 2026
Study completion
Sep 6, 2028→Jun 18, 2029
Oct 14, 2026
Eligibility
Criteria largely rewritten (98 changes)
What changed in the criteria
  • EditedAge ≥Between 18 and ≤70 years. of age
  • AddedBody weight under 115 kg (approximately 253 pounds)
  • AddedEvidence of recently acquiring HIV
  • EditedPregnancyNot pregnant or breastfeeding.
  • AddedNo recent use of medications to prevent or treat HIV
  • AddedAble and willing to provide informed consent to study and its procedures which include
  • Addedinitiating HIV medications (also called antiretroviral treatment or ART) following enrollment,
  • AddedA later, monitored pause in HIV medications (also called an analytical treatment interruption, or ATI)
  • AddedWhile pausing HIV treatment per study guidelines until resuppressed following treatment restart, agree to using barrier contraception to prevent HIV acquisition in sexual partners
  • AddedAgree to use effective contraception to prevent pregnancy in oneself and sexual partners who may become pregnant.
Inclusion criteria
  • RemovedStep 1:
  • RemovedAppropriate documentation from medical records of diagnosis of AHI prior to enrollment that includes one of the following:
  • RemovedA detectable HIV-1 RNA within 28 days prior to study entry AND a non-reactive HIV-1 antibody within 7 days prior to entry; OR
  • RemovedA detectable HIV-1 RNA or a reactive HIV-1 antibody within 28 days prior to study entry AND a negative/indeterminate Western Blot (WB) or negative/indeterminate Geenius HIV-1/HIV-2 Supplemental Assay within 7 days prior to entry; OR
  • RemovedA documented non-reactive HIV-1 antibody or negative HIV-1 RNA within 90 days prior to study entry AND a documented reactive HIV-1 antibody or positive WB that is negative for p31 band or a positive Geenius HIV-1/HIV-2 Supplemental Assay that is negative for p31 band within 7 days prior to entry; OR
  • RemovedARCHITECT or GSCOMBO S/CO ≥10 within 7 days prior to entry AND a non-reactive HIV-1 antibody within 7 days prior to entry; OR
  • RemovedARCHITECT or GSCOMBO S/CO ≥1 within 7 days prior to entry AND a non-reactive HIV-1 antibody within 7 days prior to entry AND a known prior S/CO <0.5 within 90 days prior to entry; OR
  • RemovedARCHITECT or GSCOMBO S/CO >0.5 but <10 within 7 days prior to entry AND a non-reactive HIV-1 antibody within 7 days prior to entry AND detectable HIV-1 RNA within 7 days prior to entry
  • RemovedThe following laboratory values obtained within 21 days prior to entry:
  • RemovedAbsolute neutrophil count (ANC) ˃1,000/mm3
  • RemovedHemoglobin:
  • Removed>10 g/dL for cisgender men and transgender women
  • Removed>9 g/dL for cisgender women and transgender men
  • RemovedPlatelet count ˃100,000/mm3
  • RemovedEstimated glomerular filtration rate (eGFR) ≥50 mL/min/1.73m2 using the Chronic Kidney Disease Epidemiology Collaboration (CKD-Epi) equation, with consideration for lower rates in special circumstances.
  • RemovedALT (SGPT) ≤2.5 x ULN
  • RemovedAST (SGOT) ≤2.5 x ULN
  • RemovedTotal bilirubin <1.5 x ULN
  • RemovedFor persons who are able to become pregnant, negative urine or serum pregnancy test within 24 hours prior to study entry.
  • RemovedPersons who are able to become pregnant must agree to use two methods of contraception throughout Step 1 if participating in sexual activity that could lead to pregnancy. One contraceptive method must be a highly effective method and the second method of contraception must be a barrier method.
  • RemovedParticipants of reproductive potential who engage in sexual activity that could lead to their partner's becoming pregnant must agree to use a barrier method of contraception throughout Step 1.
  • RemovedAbility and willingness to use a barrier method or abstinence from sexual intercourse with all partners who are vulnerable to HIV or whose HIV serostatus is unknown in order to prevent HIV transmission during Step 2, Step 3, and until plasma HIV-1 RNA is less than the limit of detection after ART restart in Step 4.
  • RemovedAbility and willingness to initiate ART at enrollment.
  • RemovedAbility and willingness to participate in scheduled study visits, including during the ATI, per Schedule of Evaluations (SOE).
  • RemovedAbility and willingness of participant to provide informed consent.
  • RemovedStep 2:
  • RemovedDocumented negative hepatitis B virus (HBV) surface antigen (HBsAg) obtained within 16 weeks prior to Step 2 registration.
  • RemovedDocumented negative hepatitis C virus (HCV) antibody (anti-HCV) or negative HCV RNA PCR obtained within 16 weeks prior to Step 2 registration.
  • RemovedReceipt of full doses of study infusions at enrollment (VRC07-523LS + PGT121.414.LS or placebo [Sodium Chloride for Injection USP, 0.9%]).
  • RemovedHIV-1 RNA <200 copies/mL obtained within 6 weeks prior to Step 2 registration.

…and 58 more changes, on the record history on ClinicalTrials.gov ↗

Oct 14, 2026
Primary outcomes
2 edited
What changed in the outcomes
  • EditedOccurrence of Grade ≥2 AE or SAE that are possibly, probably, or definitely related to the study bNAbs during Step 1initial ART treatmentTime frame: Week 0 to end of Step 1 → Week 0 to end of initial ART treatment (scheduled to be 60 weeks)
  • EditedTime from ART discontinuation to HIV-1 RNA ≥1,000 copies/mL for 4 consecutive weeksweekly measurements during Step 2analytical treatment interruption (ATI)Time frame: From Step 2 entry through 24 weeks after ART interruption → From start of ATI through 24 weeks after ART interruption
Oct 14, 2026
Secondary outcomes
6 edited, 7 time frame changed
What changed in the outcomes
  • EditedTime from ART discontinuation to first documented HIV-1 RNA viral rebound of ≥50 copies/mL during Step 2ATITime frame: From Step 2 entry through 24 weeks after ART interruption → From start of ATI through 24 weeks after ART interruption
  • EditedTime from ART discontinuation to first documented HIV-1 RNA viral rebound of ≥200 copies/mL during Step 2ATITime frame: From Step 2 entry through 24 weeks after ART interruption → From start of ATI through 24 weeks after ART interruption
  • EditedTime from ART discontinuation to first documented HIV-1 RNA viral rebound of ≥1000 copies/mL during Step 2ATITime frame: From Step 2 entry through 24 weeks after ART interruption → From start of ATI through 24 weeks after ART interruption
  • EditedTime from ART discontinuation to ART restart for an HIV-related reason (virologic, immunologic and clinical criteria) during Step 2ATITime frame: From Step 2 entry through 24 weeks after ART interruption → From start of ATI through 24 weeks after ART interruption
  • EditedFrequency of participants maintained off ART at each visit during Step 2ATITime frame: From Step 2 entry through 24 weeks after ART interruption → From start of ATI through 24 weeks after ART interruption
  • EditedChange in CD4+/CD8+ T-cell counts during Step 2ATITime frame: From Step 2 entry through 24 weeks after ART interruption → From start of ATI through 24 weeks after ART interruption
  • Time frameProportion of study participants who undergo ATI with HIV-1 RNA <200 copies/mL at 24 weeks after ART interruption, without indication of ART restartFrom Step 2 entry through 24 weeks after ART interruption → From start of ATI through 24 weeks after ART interruption
  • Time frameArea under the curve (AUC) of VRC07-523LS and PGT121.414.LS when administered togetherWeek 0 to end of Step 3 → Week 0 to end of ATI
  • Time frameHalf-life of VRC07-523LS and PGT121.414.LS when administered togetherWeek 0 to end of Step 3 → Week 0 to end of ATI
  • Time frameCmax of VRC07-523LS and PGT121.414.LS when administered togetherWeek 0 to end of Step 3 → Week 0 to end of ATI
  • Time frameCmin of VRC07-523LS and PGT121.414.LS when administered togetherWeek 0 to end of Step 3 → Week 0 to end of ATI
  • Time frameClearance (Cl/F) of VRC07-523LS and PGT121.414.LS when administered togetherWeek 0 to end of Step 3 → Week 0 to end of ATI
  • Time frameVolume of distribution of VRC07-523LS and PGT121.414.LS when administered togetherWeek 0 to end of Step 3 → Week 0 to end of ATI
Oct 14, 2026
Site contacts
Changed at 5 sites. See the sites
Show 5 sites
  • 2701, Northwestern University CRS · Chicago, United StatesContact b•••@northwestern.edu · •••5012→s•••@northwestern.edu · •••4997
  • 2301, Ohio State University CRS · Columbus, United StatesContact l•••@osumc.edu · •••8529→j•••@osumc.edu · •••8112
  • 6201, Penn Therapeutics CRS · Philadelphia, United StatesContact j•••@pennmedicine.upenn.edu · •••2316→J•••@pennmedicine.upenn.edu · •••1545
  • 12101, Instituto de Pesquisa Clinica Evandro Chagas (IPEC) CRS · Rio de Janeiro, BrazilContact b•••@ipec.fiocruz.br · •••9122→b•••@ini.fiocruz.br · •••9122
  • 11301, Barranco CRS · Lima, PeruContact m•••@impactaperu.org · •••7800→c•••@impactaperu.org · •••7800
Oct 14, 2026
Show all 1 update
  1. Oct 14, 2026
    2 sites added, 26 sites removed. 3 sites changed recruiting status (3 now recruiting)
    Show 3 sites
    • 2701, Northwestern University CRS · Chicago, United StatesNot yet recruiting→Recruiting
    • 6201, Penn Therapeutics CRS · Philadelphia, United StatesNot yet recruiting→Recruiting
    • 11301, Barranco CRS · Lima, PeruNot yet recruiting→Recruiting
    Show 2 added (1 United States, 1 Brazil)
    • 31473, Houston Advancing Research Team CRS · Houston, United States
    • 12201, Instituto de Pesquisas em AIDS do Rio Grande do Sul - IPARGS CRS · Porto Alegre, Brazil
    Show 26 removed
    • 1201, University of Southern California CRS · Los Angeles, United States
    • 601, University of California, Los Angeles CARE Center CRS · Los Angeles, United States
    • 701, UCSD Antiviral Research Center CRS · San Diego, United States
    • 801, University of California, San Francisco HIV/AIDS CRS · San Francisco, United States
    • 603, Harbor University of California Los Angeles Center CRS · Torrance, United States
    • 31791, Whitman-Walker Institute, Inc. CRS · Washington D.C., United States
    • 2702, Rush University CRS · Chicago, United States
    • 201, Johns Hopkins University CRS · Baltimore, United States
    • 101, Massachusetts General Hospital CRS (MGH CRS) · Boston, United States
    • 107, Brigham and Women's Hospital Therapeutics (BWH TCRS) CRS · Boston, United States
    • 2101, Washington University Therapeutics (WT) CRS · St Louis, United States
    • 7804, Weill Cornell Chelsea CRS · New York, United States
    • 30329, Columbia Physicians & Surgeons (P&S) CRS · New York, United States
    • 7803, Weill Cornell Uptown CRS · New York, United States
    • 31787, University of Rochester Adult HIV Therapeutic Strategies Network CRS · Rochester, United States
    • 3201, Chapel Hill CRS · Chapel Hill, United States
    • 3203, Greensboro CRS · Greensboro, United States
    • 2401, Cincinnati CRS · Cincinnati, United States
    • 2501, Case CRS · Cleveland, United States
    • 1001, University of Pittsburgh CRS · Pittsburgh, United States
    • 2951, The Miriam Hospital (TMH) CRS · Providence, United States
    • 3652, Vanderbilt Therapeutics (VT) CRS · Nashville, United States
    • 31443, Trinity Health and Wellness Center CRS · Dallas, United States
    • 31473, Houston AIDS Research Team CRS · Houston, United States
    • 12201, Hospital Nossa Senhora da Conceicao CRS · Porto Alegre, Brazil
    • 11302, San Miguel CRS · San Miguel, Peru
    Primary completion Apr 6, 2028→Jul 17, 2028
    Study completion Sep 6, 2028→Jun 18, 2029
    Eligibility Criteria largely rewritten (98 changes)
    What changed in the criteria
    • EditedAge ≥Between 18 and ≤70 years. of age
    • AddedBody weight under 115 kg (approximately 253 pounds)
    • AddedEvidence of recently acquiring HIV
    • EditedPregnancyNot pregnant or breastfeeding.
    • AddedNo recent use of medications to prevent or treat HIV
    • AddedAble and willing to provide informed consent to study and its procedures which include
    • Addedinitiating HIV medications (also called antiretroviral treatment or ART) following enrollment,
    • AddedA later, monitored pause in HIV medications (also called an analytical treatment interruption, or ATI)
    • AddedWhile pausing HIV treatment per study guidelines until resuppressed following treatment restart, agree to using barrier contraception to prevent HIV acquisition in sexual partners
    • AddedAgree to use effective contraception to prevent pregnancy in oneself and sexual partners who may become pregnant.
    Inclusion criteria
    • RemovedStep 1:
    • RemovedAppropriate documentation from medical records of diagnosis of AHI prior to enrollment that includes one of the following:
    • RemovedA detectable HIV-1 RNA within 28 days prior to study entry AND a non-reactive HIV-1 antibody within 7 days prior to entry; OR
    • RemovedA detectable HIV-1 RNA or a reactive HIV-1 antibody within 28 days prior to study entry AND a negative/indeterminate Western Blot (WB) or negative/indeterminate Geenius HIV-1/HIV-2 Supplemental Assay within 7 days prior to entry; OR
    • RemovedA documented non-reactive HIV-1 antibody or negative HIV-1 RNA within 90 days prior to study entry AND a documented reactive HIV-1 antibody or positive WB that is negative for p31 band or a positive Geenius HIV-1/HIV-2 Supplemental Assay that is negative for p31 band within 7 days prior to entry; OR
    • RemovedARCHITECT or GSCOMBO S/CO ≥10 within 7 days prior to entry AND a non-reactive HIV-1 antibody within 7 days prior to entry; OR
    • RemovedARCHITECT or GSCOMBO S/CO ≥1 within 7 days prior to entry AND a non-reactive HIV-1 antibody within 7 days prior to entry AND a known prior S/CO <0.5 within 90 days prior to entry; OR
    • RemovedARCHITECT or GSCOMBO S/CO >0.5 but <10 within 7 days prior to entry AND a non-reactive HIV-1 antibody within 7 days prior to entry AND detectable HIV-1 RNA within 7 days prior to entry
    • RemovedThe following laboratory values obtained within 21 days prior to entry:
    • RemovedAbsolute neutrophil count (ANC) ˃1,000/mm3
    • RemovedHemoglobin:
    • Removed>10 g/dL for cisgender men and transgender women
    • Removed>9 g/dL for cisgender women and transgender men
    • RemovedPlatelet count ˃100,000/mm3
    • RemovedEstimated glomerular filtration rate (eGFR) ≥50 mL/min/1.73m2 using the Chronic Kidney Disease Epidemiology Collaboration (CKD-Epi) equation, with consideration for lower rates in special circumstances.
    • RemovedALT (SGPT) ≤2.5 x ULN
    • RemovedAST (SGOT) ≤2.5 x ULN
    • RemovedTotal bilirubin <1.5 x ULN
    • RemovedFor persons who are able to become pregnant, negative urine or serum pregnancy test within 24 hours prior to study entry.
    • RemovedPersons who are able to become pregnant must agree to use two methods of contraception throughout Step 1 if participating in sexual activity that could lead to pregnancy. One contraceptive method must be a highly effective method and the second method of contraception must be a barrier method.
    • RemovedParticipants of reproductive potential who engage in sexual activity that could lead to their partner's becoming pregnant must agree to use a barrier method of contraception throughout Step 1.
    • RemovedAbility and willingness to use a barrier method or abstinence from sexual intercourse with all partners who are vulnerable to HIV or whose HIV serostatus is unknown in order to prevent HIV transmission during Step 2, Step 3, and until plasma HIV-1 RNA is less than the limit of detection after ART restart in Step 4.
    • RemovedAbility and willingness to initiate ART at enrollment.
    • RemovedAbility and willingness to participate in scheduled study visits, including during the ATI, per Schedule of Evaluations (SOE).
    • RemovedAbility and willingness of participant to provide informed consent.
    • RemovedStep 2:
    • RemovedDocumented negative hepatitis B virus (HBV) surface antigen (HBsAg) obtained within 16 weeks prior to Step 2 registration.
    • RemovedDocumented negative hepatitis C virus (HCV) antibody (anti-HCV) or negative HCV RNA PCR obtained within 16 weeks prior to Step 2 registration.
    • RemovedReceipt of full doses of study infusions at enrollment (VRC07-523LS + PGT121.414.LS or placebo [Sodium Chloride for Injection USP, 0.9%]).
    • RemovedHIV-1 RNA <200 copies/mL obtained within 6 weeks prior to Step 2 registration.

    …and 58 more changes, on the record history on ClinicalTrials.gov ↗

    Primary outcomes 2 edited
    What changed in the outcomes
    • EditedOccurrence of Grade ≥2 AE or SAE that are possibly, probably, or definitely related to the study bNAbs during Step 1initial ART treatmentTime frame: Week 0 to end of Step 1 → Week 0 to end of initial ART treatment (scheduled to be 60 weeks)
    • EditedTime from ART discontinuation to HIV-1 RNA ≥1,000 copies/mL for 4 consecutive weeksweekly measurements during Step 2analytical treatment interruption (ATI)Time frame: From Step 2 entry through 24 weeks after ART interruption → From start of ATI through 24 weeks after ART interruption
    Secondary outcomes 6 edited, 7 time frame changed
    What changed in the outcomes
    • EditedTime from ART discontinuation to first documented HIV-1 RNA viral rebound of ≥50 copies/mL during Step 2ATITime frame: From Step 2 entry through 24 weeks after ART interruption → From start of ATI through 24 weeks after ART interruption
    • EditedTime from ART discontinuation to first documented HIV-1 RNA viral rebound of ≥200 copies/mL during Step 2ATITime frame: From Step 2 entry through 24 weeks after ART interruption → From start of ATI through 24 weeks after ART interruption
    • EditedTime from ART discontinuation to first documented HIV-1 RNA viral rebound of ≥1000 copies/mL during Step 2ATITime frame: From Step 2 entry through 24 weeks after ART interruption → From start of ATI through 24 weeks after ART interruption
    • EditedTime from ART discontinuation to ART restart for an HIV-related reason (virologic, immunologic and clinical criteria) during Step 2ATITime frame: From Step 2 entry through 24 weeks after ART interruption → From start of ATI through 24 weeks after ART interruption
    • EditedFrequency of participants maintained off ART at each visit during Step 2ATITime frame: From Step 2 entry through 24 weeks after ART interruption → From start of ATI through 24 weeks after ART interruption
    • EditedChange in CD4+/CD8+ T-cell counts during Step 2ATITime frame: From Step 2 entry through 24 weeks after ART interruption → From start of ATI through 24 weeks after ART interruption
    • Time frameProportion of study participants who undergo ATI with HIV-1 RNA <200 copies/mL at 24 weeks after ART interruption, without indication of ART restartFrom Step 2 entry through 24 weeks after ART interruption → From start of ATI through 24 weeks after ART interruption
    • Time frameArea under the curve (AUC) of VRC07-523LS and PGT121.414.LS when administered togetherWeek 0 to end of Step 3 → Week 0 to end of ATI
    • Time frameHalf-life of VRC07-523LS and PGT121.414.LS when administered togetherWeek 0 to end of Step 3 → Week 0 to end of ATI
    • Time frameCmax of VRC07-523LS and PGT121.414.LS when administered togetherWeek 0 to end of Step 3 → Week 0 to end of ATI
    • Time frameCmin of VRC07-523LS and PGT121.414.LS when administered togetherWeek 0 to end of Step 3 → Week 0 to end of ATI
    • Time frameClearance (Cl/F) of VRC07-523LS and PGT121.414.LS when administered togetherWeek 0 to end of Step 3 → Week 0 to end of ATI
    • Time frameVolume of distribution of VRC07-523LS and PGT121.414.LS when administered togetherWeek 0 to end of Step 3 → Week 0 to end of ATI
    Site contacts Changed at 5 sites. See the sites
    Show 5 sites
    • 2701, Northwestern University CRS · Chicago, United StatesContact b•••@northwestern.edu · •••5012→s•••@northwestern.edu · •••4997
    • 2301, Ohio State University CRS · Columbus, United StatesContact l•••@osumc.edu · •••8529→j•••@osumc.edu · •••8112
    • 6201, Penn Therapeutics CRS · Philadelphia, United StatesContact j•••@pennmedicine.upenn.edu · •••2316→J•••@pennmedicine.upenn.edu · •••1545
    • 12101, Instituto de Pesquisa Clinica Evandro Chagas (IPEC) CRS · Rio de Janeiro, BrazilContact b•••@ipec.fiocruz.br · •••9122→b•••@ini.fiocruz.br · •••9122
    • 11301, Barranco CRS · Lima, PeruContact m•••@impactaperu.org · •••7800→c•••@impactaperu.org · •••7800
    + 3 other changes: verification date, description and conditions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05719441
Responsible party
Sponsor
First posted
Feb 9, 2023
Start date
Aug 19, 2024
Primary completion
Jul 17, 2028 (estimated)
Completion
Jun 18, 2029 (estimated)
Last update
Oct 14, 2026

Study contacts

Trevor Crowell, MD, PhD
study chair · U.S. Military HIV Research Program CTU
Roberto Arduino, MD
study chair · Houston AIDS Research Team CRS

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion